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WILLINGNESS TO PAY FOR HIV PREVENTION:
A STUDY OF HIGH- AND LOW-RISK GROUPS
Flanders S
Saint Louis University, School of Public Health,
St. Louis, MO, USA
OBJECTIVE: This purpose of this study was to estimate
the value of I-llV prevention using the contingent valuation
methodology.
METHODS: Two convenience samples of 452 high-risk
individuals (homosexual) and 155 low-risk individuals
(heterosexual) were collected from selected sites across
the state of Missouri. Subjects completed a 60 item ques-
tionnaire on their knowledge, attitudes, beliefs, and sex-
ual behaviors. A series of willingness to pay (WTP) ques-
tions were asked to estimate the value of 98% protection
(i.e., condom use) and 100% protection (i.e., abstinence)
from HIV infection. Additionally, two willingness to be
paid (WTBP) questions were asked to estimate the cost of
behavior change.
RESULTS: The results of the study showed high-risk in-
dividuals placed a greater value on the benefits of HIV
prevention than did individuals at low-risk of HIV infec-
tion. The benefits of condom use against infection from
HIV were valued at $261/month for subjects in the high-
risk sample and $238/month for individuals in the low-
risk sample. The average monetary benefits of abstinence
against HIV infection were estimated at $305/month for
high-risk individuals, compared to $249/month among
individuals in the low-risk sample. Utility for each pre-
ventive behavior (condom use and abstinence) was calcu-
lated using a cost-to-benefit ratio (WTBPIWTP). Utilities
were regressed on demographic and risk variables. A
high-risk individual's utility for 98% protection was as-
sociated with greater exposure risk to HIV and knowl-
edge of an AIDS-related death. The low-risk sample was
not statistically significant, and no statistical relation-
ships were found between independent variables.
CONCLUSIONS: While subject to methodological limi-
tations, the results from this research provide estimates of
the value of HIV prevention strategies. Further research
in the area of WTP and HIV prevention is advocated
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PRESCRIBING PATTERNS FOR TREATMENT OF
UPPER RESPIRATORY INFECTIONS
McLaughlin TP, Lalla DV, Kozma CM
College of Pharmacy, University of South Carolina, Columbia.
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OBJECTIVE: To characterize the treatment received by
patients with an upper respiratory infection (URI) in the
South Carolina Medicaid population during 1996. Liter-
ature suggests that antibiotics are commonly prescribed
to patients presenting with symptoms of an URI even
though less than 20% are bacterial in origin. Overuse of
Abstracts
antibiotics may lead to antibiotic resistance and unneces-
sary costs.
METHODS: Patients with a diagnosis for a cold (lCD-9-
CM 460) or URI (ICD-9-CM 465) between 01/01/96 and
12/31/96 were identified. The study design allowed for
each subject to have multiple diagnoses (episodes). For
each episode, subjects with prescriptions for antibiotics
or symptomatic cold medications within 7 days after the
diagnosis were identified. Any episode within 14 days of
a claim for a bacterial infection, sinusitis or otitis was re-
moved from the study, to rule out the possibility that the
antibiotic was related to another infection.
RESULTS: A total of 22,791 patients was eligible for in-
clusion in the study, incurring 27,847 episodes (Range 1-7
episodes). 9468 (34%) of the episodes were treated with
an antibiotic, accounting for $166,702.33. This rate is
lower than that seen in previous studies; however, our in-
clusion were more stringent than was used previously. If
20% of URIs are bacterial, approximately 3,900 of these
antibiotics were unnecessary. A 25% reduction in the ex-
cess prescriptions would provide a cost savings of
$17,169.75 for South Carolina Medicaid.
CONCLUSION: In spite of comprehensive documenta-
tion arguing against using antibiotics for treatment of
URIs, it appears that they still remain a popular choice
for physicians, with 34% of subjects in this study receiv-
ing antibiotics. This represents an area for cost savings
for the South Carolina Medicaid Program.
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OBJECTIVE: To develop a decision analytical model for
current and anticipated management of cytomegalovirus
infection and disease in renal transplant patients.
METHODS: We developed a decision analytical model
for the US and UK, containing currently recognized man-
agement strategies for cytomegalovirus infection and dis-
ease in renal transplant patients. The model enables com-
parison of current management strategies, assessment of
anticipated strategies, and the impact of country-specific
practice. Outcomes are expressed as "number of cases
avoided" and "quality-adjusted time without symptoms
or toxicity" (Q-TWIST).
RESULTS: The model indicates that in the UK, for donor
seropositive/recipient seronegative (D+/R-) patients,
prophylaxis with IV ganciclovir cost an additional
27,000 GBP, whereas testing for virus and preemptive
therapy with IV ganciclovir costs an additional 18,000
GBP per case of CMV avoided compared with a "wait
and treat" strategy. Modeling indicates that prophlaxis
